Neoadjuvant intralesional daromun (L19IL2/L19TNF) in resectable locally advanced melanoma: An update on the primary outcome and sensitivity analyses (EFS) from the PIVOTAL phase 3 trial. Late-stage ...
Rab11 family interacting proteins as regulators of T cell recognition and infiltration in triple negative breast cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...
Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems? The following represents disclosure information provided by authors of this manuscript. All relationships ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
My NIH-funded research has been accepted by JCO Journals. Now what? If your article is Open Access: JCO Journals will deposit all open access articles to PubMed Central on behalf of the authors. If ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma. This is an ASCO Meeting Abstract from ...
Neoadjuvant Immunotherapy for Colorectal Cancer: Too Good to Be True? Despite significant progress and improving outcomes in the management of plasma cell disorders, AL amyloidosis remains ...
Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary ...
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) ...
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies A.C.T. is the recipient of an International Association for the Study of Lung Cancer Fellowship from ...
Supported in part by the National Cancer Institute of the National Institutes of Health (Grant No. K08CA234225, G.R.W.), the American Cancer Society (Grant No. ACS-18-162-59-IRG, G.R.W.) and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results